Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|April 11, 2008
Inhalable insulin prescribing information revised to include lung malignancy occurrence
Pfizer revises package insert after reports of lung cancer in patients receiving their inhaled insulin.
Advertisement
Pfizer has issued letters to both healthcare professionals and patients to inform them of six reported cases of newly diagnosed primary lung malignancy during clinical trials in patients using their insulin human [rDNA origin] inhalation powder (
Advertisement
Related to this article
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
3
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
4
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
5